Comparison of clinical effects of pemetrexed combined with cisplatin and docetaxel with cisplatin in treatment of non-small cell lung cance
Objective To observe the effect of pemetrexed combined with cisplatin and docetaxel combined with cisplatin in the treatment of non-small cell lung cancer and the changes of tumor markers before and after treatment.Methods A total of 110 patients with non-small cell lung cancer admitted to the hospital from January to December 2022 were includ-ed in the study.According to different drug groups,55 patients treated with docetaxel+cisplatin were selected as the con-trol group,and 55 patients treated with pemetrexed+cisplatin were selected as the observation group.The clinical efficacy of two groups of patients under different treatment schemes was compared.Results The remission rate of observation group was 96.36％,which was significantly higher than that of control group(81.81％)(P＜0.05).The median survival time of the observation group was(18.37±6.43)months,which was longer than that of the control group(8.21±3.98)months(P＜0.05),but the time without survival progression and one-year survival rate were(5.38±0.52)months and 65.45％,respectively,with no statistical significance compared with the control group(P＞0.05).There was no signifi-cant difference in carbohydrate antigen 125(CAl25)and Cytokeratin-19-fragment(CYFRA21-1)levels between the two groups before treatment(P＞0.05).After treatment,all of them were lower than that of control group(P＜0.05).The incidence of adverse reactions in observation group was 1.81％,which was lower than that in control group(16.36％)(P＜0.05).Conclusion Pemetrexed plus cisplatin is better than docetaxel plus cisplatin in the treatment of patients with non-small cell lung cancer,which has high application value and is worth promoting.
NETL
NSTL
万方数据
